The findings lay the groundwork for tests that can identify whether the disease is likely to progress rapidly.

The haploidentical transplant process has vastly expanded the pool of bone marrow or stem cell donors.

Scientists aim to gather knowledge that improves future immunotherapies.

The approved therapies have roiled the insurance approval process, which has led to delays and denials of coverage.

Keith Rohleder participated in a clinical trial—which included chemotherapy and radiation—and then received a stem cell transplant.

Outcomes are improving for this hard-to-treat blood cancer.

Low doses of the infamous poison could help stop some forms of leukemia in their tracks, say researchers.

Approval was based on improves progression-free survival in the MURANO trial.

Oncologists are excited about the increased options available to patients, and about the promise of even more new therapies to come.